Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001628280-21-002125
Filing Date
2021-02-12
Accepted
2021-02-12 16:59:33
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G schedule13g_aegleabiothera.htm SC 13G 90158
  Complete submission text file 0001628280-21-002125.txt   91711
Mailing Address 115 W WASHINGTON STREET SUITE 1680 SOUTH INDIANAPOLIS IN 46204
Business Address 115 W WASHINGTON STREET SUITE 1680 SOUTH INDIANAPOLIS IN 46204 (317) 429-0140
Lilly Ventures Fund I LLC (Filed by) CIK: 0001575852 (see all company filings)

EIN.: 264769290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Subject) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-89456 | Film No.: 21629041
SIC: 2834 Pharmaceutical Preparations